Liu Hong, Li Ping, Chen Liang, Jian Chao, Li Zonghuan, Yu Aixi
Department of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, China.
Department of Surgery, Experimental Surgery and Regenerative Medicine, Ludwig-Maximilians University, München, Germany.
Onco Targets Ther. 2017 Nov 1;10:5229-5236. doi: 10.2147/OTT.S143974. eCollection 2017.
MicroRNAs (miRNAs) have been considered as promising diagnostic biomarkers for many diseases, especially for cancers. Numerous studies have reported the value of miRNAs in the diagnosis of osteosarcoma (OS), but the results vary greatly across different studies. Therefore, we conducted this meta-analysis to assess the prospective diagnostic value of miRNAs in diagnosing OS. All relevant articles from prior to July 28, 2017 were selected from PubMed, EMBASE, Web of Science, Cochrane Library, Chinese National Knowledge Infrastructure, and Wan-fang databases. The Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) was performed to assess the quality of each article. A random-effects model was used to pool the sensitivity and specificity of the positive likelihood ratio (PLR), negative likelihood ratio (NLR) and, diagnostic odds ratio (DOR) together with the area under the curve (AUC) to evaluate diagnostic values. Seventeen studies comprising 2,214 OS patients and 1,534 healthy humans were included in our meta-analysis. The pooled estimations indicated that the miRNAs had a high accuracy for diagnosing OS, with a sensitivity of 0.82, specificity of 0.88, PLR of 10.96, NLR of 0.20, DOR of 54.55, and AUC of 0.93. Twenty-five miRNAs were differentially expressed in OS, including 17 upregulated and 8 downregulated. These miRNAs were correlated with survival time, tumor size, cell differentiation, tumor node metastasis staging, metastasis, tumor/cell invasion, pathological type, and response to radiotherapy and chemotherapy. Several different miRNAs are expressed in OS, and some of them might be potential biomarkers for the early diagnosis of OS.
微小RNA（miRNA）已被视为多种疾病，尤其是癌症的有前景的诊断生物标志物。众多研究报道了miRNA在骨肉瘤（OS）诊断中的价值，但不同研究结果差异很大。因此，我们进行了这项荟萃分析，以评估miRNA在诊断OS中的前瞻性诊断价值。从PubMed、EMBASE、科学网、Cochrane图书馆、中国知网和万方数据库中筛选了2017年7月28日前的所有相关文章。采用诊断准确性研究质量评估-2（QUADAS-2）来评估每篇文章的质量。使用随机效应模型汇总阳性似然比（PLR）、阴性似然比（NLR）和诊断比值比（DOR）的敏感性和特异性，以及曲线下面积（AUC）来评估诊断价值。我们的荟萃分析纳入了17项研究，共2214例OS患者和1534例健康人。汇总估计表明，miRNA对OS诊断具有较高准确性，敏感性为0.82，特异性为0.88，PLR为10.96，NLR为0.20，DOR为54.55，AUC为0.93。25种miRNA在OS中差异表达，其中17种上调，8种下调。这些miRNA与生存时间、肿瘤大小、细胞分化、肿瘤淋巴结转移分期、转移、肿瘤/细胞侵袭、病理类型以及对放疗和化疗的反应相关。几种不同的miRNA在OS中表达，其中一些可能是OS早期诊断的潜在生物标志物。
